Alphamab Oncology is an investment holding company. The company is headquartered in Suzhou, Jiangsu and currently employs 484 full-time employees. The company went IPO on 2019-12-12. The Company’s in-house pipeline consists of antibody-drug conjugates (ADCs), monoclonal antibodies and bispecific antibodies in staggered development status in oncology. The Company’s product pipeline includes KN046 (PD-L1/CTLA-4 bispecific antibody), KN026 (HER2/HER2 bispecific antibody), KN035 (SubQ PD-L1), JSKN003 (HER2 biparatopic ADC), JSKN016(HER3/TROP2 bispecific antibody ADC), JSKN033(subcutaneous co-formulation of JSKN003 and KN035), used for indications such as 1L sq NSCLC, 1L HER2+ BC, 1L biliary track cancer, advanced solid tumors, HER2-expressing solid tumors and others.
09966.HK stock price ended at $8.97 on 星期五, after rising 0.79%
On the latest trading day Feb 13, 2026, the stock price of 09966.HK rose by 0.79%, climbing from $9.30 to $8.97. During the session, the stock saw a volatility of 5.68%, with prices oscillating between a daily low of $8.80 and a high of $9.30. Notably, trading volume dropped by 217.0K shares on the last day despite the price increase, which may signal a potential uptick in risk in the near term. A total of 1.1M shares were traded, equating to a market value of approximately $8.6B.